Micromet drug sees leukemia remission in Phase II trial

06/12/2011 | Bloomberg

Interim results of a midstage study indicate that blinatumomab, an investigational drug from Micromet, produced complete remission in nine of 12 patients whose acute lymphoblastic leukemia had relapsed after conventional treatment. The positive data could bring accelerated FDA approval, an analyst said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY